An interventional study of 311-nm Ti:Sapphire laser and 308-nm excimer laser in Vitiligo, sponsored by The Catholic University of Korea. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-19.
Sponsored by The Catholic University of Korea · Not applicable, Interventional, and Treatment
A randomized controlled non-inferiority trial based on split-body was planned to compare the efficacy of 308-nm excimer laser and 311-nm Ti:Sapphire laser in patients with vitiligo.
The 308-nm excimer laser (EL) has been widely used for localized vitiligo. Recently, the 311-nm Ti:Sapphire laser (TSL) was developed to treat patients with vitiligo. To compare the efficacy of TSL vs. EL in the treatment of vitiligo.
A randomized controlled non-inferiority trial based on split-body was planned. The paired symmetric vitiliginous lesions will be randomized to either TSL or EL treatment groups. All lesions will be treated twice weekly for a total of 12-week period. The degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks, and the non-inferiority margin was set at 10%. Overall 16 patients will be enrolled.
298 studies on the registry are indexed under Vitiligo; 69 are open to participants now.
This study's planned enrollment of 16 is below the median of 30 across 227 interventional studies indexed under Vitiligo.
Browse Vitiligo studies →The Catholic University of Korea is the lead sponsor of 150 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All lesions were treated twice weekly for a total of 12-week period.
Device: 311-nm Ti:Sapphire laser
All lesions were treated twice weekly for a total of 12-week period.
Device: 308-nm excimer laser
Pallas, LaserOptek, South Korea
XTRAC, PhotoMedex, US
The repigmentation rate (change from baseline) of the vitiliginous patch
The degree of repigmentation will be assessed as % from baseline by using a computer program.
Time frame: Baseline and 12 weeks
The adverse effects of both two laser treatments
Time frame: At 4 weeks, 8 weeks, and 12 weeks
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Catholic University of Korea